Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Substrate Metabolism Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

NCT04526197
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Celecoxib
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Resistance Training on Substrate Metabolism During the Menstrual Cycle

NCT04024826
View directory record Official record
Conditions
Menstrual Cycle, Substrate Metabolism
Interventions
EFP, LFP, ELP, LLP
Behavioral
Lead sponsor
Southern Illinois University Edwardsville
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Edwardsville, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Breathe Light Study

NCT01976455
View directory record Official record
Conditions
Over-eating, Obesity
Interventions
20% fewer calories, 40% fewer calories
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

NCT00304512
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breakfast Consumption and Energy Balance in Active Adult Males

NCT04862208
View directory record Official record
Conditions
Energy Intake, Substrate Utilization, Hormones, Satiety
Interventions
Maltodextrin supplement, Whey supplement, Water
Dietary Supplement
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ordered Eating and Acute Exercise

NCT06242015
View directory record Official record
Conditions
Glucose Metabolism Disorders, Hunger
Interventions
Carbohydrate-first meal, Carbohydrate-last meal
Other
Lead sponsor
Old Dominion University
Other
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pre-workout Supplement Versus Caffeine on Energy Expenditure.

NCT04539054
View directory record Official record
Conditions
Healthy
Interventions
ENGN Shred, Nutricost caffeine powder, Crystal Light
Dietary Supplement
Lead sponsor
Northern Illinois University
Other
Eligibility
19 Years to 29 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
DeKalb, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Eating Beans on Metabolism

NCT06123208
View directory record Official record
Conditions
Overweight
Interventions
Whole cooked pinto bean, Pinto bean flour, Control
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
19 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

NCT04526210
View directory record Official record
Conditions
Wilson Disease
Interventions
ALXN1840, Bupropion Hydrochloride
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Withdrawn Phase 2 Interventional

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

NCT06104358
View directory record Official record
Conditions
Diabete Type 2, Obesity
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Effect of Dietary Macronutrient Composition

NCT01371396
View directory record Official record
Conditions
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Low-fat diet, Low-carbohydrate diet
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

NCT00214500
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Los Angeles, California • Decatur, Georgia • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 4 Interventional Results available

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

NCT04718779
View directory record Official record
Conditions
Gaucher Disease
Interventions
Digital Engagement Application (GD App), No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ketone Supplements and Substrate Oxidation and Physical Performance

NCT04737694
View directory record Official record
Conditions
Ketosis, Glucose Metabolism
Interventions
Ketone ester, Glucose
Dietary Supplement
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 39 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Metabolic Adaptations to High-fat Diet

NCT06537401
View directory record Official record
Conditions
Adiposity, Insulin Sensitivity, Impaired Glucose Tolerance, Metabolic Disturbance
Interventions
Hypercaloric, High Fat Diet
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
20 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Caloric Content and Timing of Meal on Postprandial Substrate Oxidation and Pulse Wave Analysis

NCT07122765
View directory record Official record
Conditions
Feeding, Metabolism, Indirect Calorimetry, Blood Flow Velocity, Pulse Wave Analysis, Pulse Wave Velocity, Carbohydrate Metabolism, Fatty Acid Metabolism, Healthy Participants
Interventions
Mixed Meal Feeding Challenge
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

NCT00925301
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat hydrochloride, Placebo
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
16 Years to 74 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Decatur, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Results available

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

NCT01358968
View directory record Official record
Conditions
Cancer
Interventions
LY2603618, Desipramine, Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

NCT00891202
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
San Francisco, California • New Haven, Connecticut • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 3, 2026, 9:47 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Fructose: Substrate, Stimulus, or Both?

NCT04168372
View directory record Official record
Conditions
Insulin Resistance, Insulin Sensitivity, Pre Diabetes
Interventions
High fructose, fructose labeled meal, High fructose, pyruvate labeled meal, Low fructose, fructose labeled meal, Low fructose, pyruvate labeled meal
Other
Lead sponsor
Touro University, California
Other
Eligibility
20 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Measurement of Nutritional Substrate Utilization in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00714220
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases
Interventions
Not listed
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
20 Years to 85 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

NCT00526071
View directory record Official record
Conditions
Fabry Disease
Interventions
migalastat HCl
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Decatur, Georgia • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Substrate Cycling in Energy Metabolism

NCT00361751
View directory record Official record
Conditions
Burns, Insulin Resistance
Interventions
fenofibrate
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
4 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance

NCT01240252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Human insulin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 3, 2026, 9:47 AM EDT